{"filing":{"accession_number":"0001701541-26-000023","cik":"0001701541","ticker":"BDTX","company_name":"Black Diamond Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"bdtx-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1701541/000170154126000023/bdtx-20260805.htm"},"events":[{"id":25217,"run_id":22881,"accession_number":"0001701541-26-000023","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Black Diamond Therapeutics disclosed its financial results for the six months ended June 30, 2026 via a press release furnished as Exhibit 99.1 under Item 2.02. The filing includes consolidated balance sheet data, statements of operations with revenue and net loss figures, and cash position disclosures. This is a standard earnings release announcement for a clinical-stage company reporting quarterly/semi-annual financial results.","company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25983,"accession_number":"0001701541-26-000023","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Black Diamond Therapeutics disclosed its financial results for the six months ended June 30, 2026 via a press release furnished as Exhibit 99.1 under Item 2.02. The filing includes consolidated balance sheet data, statements of operations with revenue and net loss figures, and cash position disclosures. This is a standard earnings release announcement for a clinical-stage company reporting quarterly/semi-annual financial results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:20:00.721153+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25983,"accession_number":"0001701541-26-000023","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Black Diamond Therapeutics disclosed its financial results for the six months ended June 30, 2026 via a press release furnished as Exhibit 99.1 under Item 2.02. The filing includes consolidated balance sheet data, statements of operations with revenue and net loss figures, and cash position disclosures. This is a standard earnings release announcement for a clinical-stage company reporting quarterly/semi-annual financial results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:20:00.721153+00:00","company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","filing_date":"2026-08-05"}]}